RxDoctor Payments Data

James Robinson, MD

Internal Medicine · Covington, LANPI 1275513483

Payments from drug & device makers

$2,152in general payments, 2019–2025

Across 87 payments — averaging $24.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$566
  • Lilly USA, LLC$342
  • Novo Nordisk$219
  • AbbVie$215
  • Boehringer Ingelheim$171
  • GSK$161
  • plus $478 from 10 others

What the payments were for

  • Food & beverage$2,152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,152 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$52,623
Medicare patients
130
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide50$62,949
FarxigaDapagliflozin Propanediol26$34,152
EliquisApixaban34$29,835
JardianceEmpagliflozin37$29,686
OzempicSemaglutide12$17,017
XareltoRivaroxaban25$15,416
SynthroidLevothyroxine Sodium38$4,442
DayvigoLemborexant13$4,300
Irbesartan147$3,094
SymbicortBudesonide/Formoterol Fumarate12$2,855
Dexlansoprazole DrDexlansoprazole11$2,598
Rosuvastatin Calcium204$2,232
Pantoprazole Sodium155$2,033
Metoprolol Succinate133$1,926
Testosterone29$1,828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$342$62,94950 claims
AstraZenecaFarxiga, Symbicort$79$37,00638 claims
PfizerEliquis$14$29,83534 claims
Boehringer IngelheimJardiance$171$29,68637 claims
Novo NordiskOzempic$219$17,01712 claims
AbbVieSynthroid$215$4,44238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →